302 related articles for article (PubMed ID: 28410878)
1. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature.
Pérez-López J; Moltó-Abad M; Muñoz-Delgado C; Morales-Conejo M; Ceberio-Hualde L; Del Toro M
Mol Genet Metab; 2018 Jul; 124(3):216-227. PubMed ID: 29801985
[TBL] [Abstract][Full Text] [Related]
3. Agreement between the results of meta-analyses from case reports and from clinical studies regarding the efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age: An example of case reports meta-analyses as an useful tool for evidence-based medicine in rare diseases.
Sampayo-Cordero M; Miguel-Huguet B; Pardo-Mateos A; Moltó-Abad M; Muñoz-Delgado C; Pérez-López J
Mol Genet Metab; 2018 Feb; 123(2):69-75. PubMed ID: 29336994
[TBL] [Abstract][Full Text] [Related]
4. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
Xue Y; Richards SM; Mahmood A; Cox GF
Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
6. Limited data to evaluate real-world effectiveness of enzyme replacement therapy for mucopolysaccharidosis type I.
Kuiper GA; Nijmeijer SCM; Roelofs MJM; van der Lee JH; Hollak CEM; Bosch AM
J Inherit Metab Dis; 2019 Sep; 42(5):762-775. PubMed ID: 31020996
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.
Dornelles AD; Artigalás O; da Silva AA; Ardila DLV; Alegra T; Pereira TV; Vairo FPE; Schwartz IVD
PLoS One; 2017; 12(8):e0184065. PubMed ID: 28859139
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy with laronidase (Aldurazyme
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD009354. PubMed ID: 31211405
[TBL] [Abstract][Full Text] [Related]
11. Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome.
Thomas JA; Jacobs S; Kierstein J; Van Hove J
J Inherit Metab Dis; 2006 Dec; 29(6):762. PubMed ID: 17089217
[TBL] [Abstract][Full Text] [Related]
12. Anthropometric data of 14 patients with mucopolysaccharidosis I: retrospective analysis and efficacy of recombinant human alpha-L-iduronidase (laronidase).
Tylki-Szymanska A; Rozdzynska A; Jurecka A; Marucha J; Czartoryska B
Mol Genet Metab; 2010 Jan; 99(1):10-7. PubMed ID: 19783188
[TBL] [Abstract][Full Text] [Related]
13. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
Laraway S; Mercer J; Jameson E; Ashworth J; Hensman P; Jones SA
J Pediatr; 2016 Nov; 178():219-226.e1. PubMed ID: 27788836
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
[TBL] [Abstract][Full Text] [Related]
17. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships.
Al-Sannaa NA; Bay L; Barbouth DS; Benhayoun Y; Goizet C; Guelbert N; Jones SA; Kyosen SO; Martins AM; Phornphutkul C; Reig C; Pleat R; Fallet S; Ivanovska Holder I
Orphanet J Rare Dis; 2015 Oct; 10():131. PubMed ID: 26446585
[TBL] [Abstract][Full Text] [Related]
18. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
[TBL] [Abstract][Full Text] [Related]
19. Progressive eye pathology in mucopolysaccharidosis type I mice and effects of enzyme replacement therapy.
Gonzalez EA; Visioli F; Pasqualim G; de Souza CFM; Marinho DR; Giugliani R; Matte U; Baldo G
Clin Exp Ophthalmol; 2020 Apr; 48(3):334-342. PubMed ID: 31925897
[TBL] [Abstract][Full Text] [Related]
20. Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans.
de Ru MH; van der Tol L; van Vlies N; Bigger BW; Hollak CE; Ijlst L; Kulik W; van Lenthe H; Saif MA; Wagemans T; van der Wal WM; Wanders RJ; Wijburg FA
J Inherit Metab Dis; 2013 Mar; 36(2):247-55. PubMed ID: 22991166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
